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Ligand molecules that can recognize and interact with cancer cell surface marker proteins with high affinity and 
specificity should greatly aid the development of novel cancer diagnostics and therapeutics. HER-2/ErbB2/Neu 
(HER-2), a member of the epidermal growth factor receptor family, is specifically overexpressed on the surface of 
breast cancer cells and serves as both a useful biomarker and a therapeutic target for breast cancer. In this study, we 
aimed to isolate RNA aptamers that specifically bind to a HER-2-overexpressing human breast cancer cell line, 
SK-BR-3, using Cell-SELEX strategy. The selected aptamers showed strong affinity to SK-BR-3, but not to MDA- 
MB-231, a HER-2-underexpressing breast cancer cell line. In addition, we confirmed the specific targeting of 
HER-2 receptor by aptamers using an unrelated mouse cell line overexpressing human HER-2 receptor. The 
HER-2-targeting RNA aptamers could become a useful reagent for the development of breast cancer diagnostics and 
therapeutics.
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Introduction
Ligand molecules which can bind to a specific cancer cell 
type, by interacting with cancer cell surface proteins with high 
affinity and specificity, is critical for developing cancer diag-
nostics and therapeutics. The ligand molecule in turn can be 
utilized to identify the cancer biomarker proteins.1 Under-
standing the biology of these biomarkers can further facilitate 
the development of novel cancer therapeutics. 
HER-2/ErbB2/Neu (HER-2) is a transmembrane receptor 
tyrosine kinase, which is a member of the epidermal growth 
factor receptor family.2 Overexpression of HER-2 is observed 
in 20 to 30% of breast cancers, and predicts for a poor clinical 
outcome.3 A HER-2 ectodomain-directed monoclonal antibody 
(trastuzumab or Herceptin) has been approved for the treat-
ment of breast cancer.2 HER-2 is also an attractive target for 
in vivo imaging4 and targeted drug delivery for breast cancer.5
Aptamers are single-stranded DNA or RNA oligonucleotides 
which can fold into specific three-dimensional conformation 
to bind targets with high affinity and specificity.6 The targets 
for aptamers include small molecules, peptides, proteins, and 
even whole cells.7 High affinity aptamers for specific targets can 
be isolated from a randomized oligonucleotide library in vitro 
by using the Systematic Evolution of Ligands by EXponential 
enrichment (SELEX) process.8-10
Aptamers have several advantages over antibodies, such as 
smaller size, better tissue penetration, ease of chemical modi-
fication, and the lack of immune responses. For in vivo imaging 
applications, aptamers are especially superior over antibodies 
with faster kinetics and higher signal-to-noise ratio, owing to 
their smaller size.11 Aptamers can decorate the surface of mag-
netic nanoparticles used for magnetic resonance imaging 
(MRI), to enhance the specificity of imaging.12 As a cancer 
therapeutics, aptamers can either directly inhibit the cancer 
growth signaling pathway by blocking growth factor or 
growth factor receptors,13 or be used as “escort aptamers”11 to 
deliver therapeutic molecules such as cytotoxic agents, radio-
nuclides, or even small interfering RNAs (siRNAs) to the target 
cells. Therefore, generation of specific aptamers targeting 
different cancer cell types and cancer cell surface proteins would 
greatly aid the development of novel cancer diagnostics and 
therapeutics.
However, isolation of aptamers targeting specific cancer 
cell types is challenging because for many cancer cell types, 
specific surface biomarker proteins are not known. Even if the 
biomarker protein specific to certain cancer type is known, 
membrane protein is typically difficult to express and purify, 
or the purified membrane protein might not have the native 
conformation as it is present on the cell membrane, so that 
aptamers selected against purified protein might not recog-
nize the same protein on the cell surface.14 Therefore, a method 
is required to isolate aptamers targeting membrane proteins in 
its native form as presented on the cell surface.
Recent development of Cell-SELEX strategy allows resear-
chers to generate aptamers specifically targeting proteins on 
the cell surface,14 or specific cancer cell types even when the 
biomarker protein is not known.15 In this study, we report the 
selection of RNA aptamers targeting HER-2-overexpressing 
SK-BR-3 cells using Cell-SELEX strategy. The selected apta-
mers showed strong affinity to SK-BR-3, but not to MDA- 
MB-231, a HER-2-underexpressing breast cancer cell line. 
Specific targeting of HER-2 receptor by aptamers was further 
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confirmed by demonstrating that the aptamer could bind to an 
unrelated mouse cell line, NIH3T3, when it overexpresses the 
human HER-2 receptor.
Experimental Section
Cell and culture conditions. Human breast cancer cell lines 
SK-BR-3, MDA-MB-231, and a mouse fibroblast cell line, 
NIH-3T3, were obtained from the American Type Culture 
Collection and cultured at 37 oC in McCoy’s 5A media (Welgene) 
for SK-BR-3, RPMI-1640 media (Gibco BRL) for MDA-MB- 
231 and DMEM media (Gibco BRL) for NIH-3T3 supplemented 
with 10% fetal bovine serum and antibiotics (100 U/mL peni-
cillin and 100 ug/mL streptomycin, Gibco BRL), respectively.  
NIH3T6.7 cell, which is a HER-2 overexpressing NIH-3T3 
cell line, was maintained in DMEM media. Cells were regularly 
subcultured to maintain exponential growth. 
Transfection. For counter SELEX using siHER-2, SK-BR-3 
cells were plated in 60 mm plates in complete medium without 
antibiotics and incubated for 24 h until they reached 50% con-
fluency. 10 nM of siRNA was then transfected using Lipofec-
tamine 2000 reagent (Invitrogen), according to the manufac-
turer’s instructions. After 24 h, the transfected cells were 
counted and 1 × 106 cells were incubated with the aptamer pool.
SELEX library and primers. The PAGE-purified random 
library 40 mer (5’-ATA CCA GCT TAT TCA ATT NNN NNN 
NNN NNN NNN NNN NNN NNN NNN NNN NNN NNN 
NNN NAG ATA GTA AGT GCA ATC T-3’) was used to generate 
the RNA library.  N40 upstream primer (5’-GGTAATACGAC-
TCACTATAGGGAGATACCAGCTTATTCAATT-3’) and down-
stream primer (5’-AGATTGCACTTACTATCT-3’) were used 
for library PCR. A TAMRA-labeled 3’-primer (5’-TAMRA- 
AGATTGCACTTACTATCT-3’) was annealed with the aptamer 
for affinity test using fluorescence microscopy.
Cell SELEX. Cells were harvested by trypsinization and 1 × 
106 cells were recovered in complete media at 37 oC for 30 
min. 160 pmole of RNA library was dissolved in binding 
buffer (4.5 g/L glucose, 5 mM MgCl2, 0.1 mg/mL yeast tRNA, 
1 mg/mL BSA in Dulbecco’s PBS) and denatured at 95 oC for 
5 min followed by cooling on ice immediately. The recovered 
cells were washed twice with washing buffer (4.5 g/L glucose, 
5 mM MgCl2 in Dulbecco’s PBS) and incubated with prepared 
RNA library in binding buffer at 4 oC for 45 min. Cells were 
washed twice with washing buffer, and then the bound RNA 
aptamers were eluted by heating at 95 oC for 5 min and sepa-
rated by phenol:chloroform:isoamyl alcohol (PCI, Bioneer) 
and chloroform extraction. The obtained RNA was reverse- 
transcribed using ImProm-II™ Reverse Transcription System 
(Promega) and PCR-amplified. The purified PCR product 
was subjected to in vitro transcription using T7 polymerase 
(Ambion). In the case of negative selection the bound RNA 
pool was incubated with the HER-2 negative cell line (MDA- 
MB-231) or siHER-2-transfected SK-BR-3 cells, respectively.
Quantitative RT-PCR. Both the pre-bound (in-put) aptamer 
pool and post-bound (out-put) aptamer pool were used as a 
template for cDNA synthesis, which was performed with the 
ImProm-II™ Reverse Transcription System (Promega) accor-
ding to the manufacture’s protocol. Aliquots (1/250) of the 
cDNA reaction mixture were analyzed by quantitative real- 
time PCR on a Step-One real-time PCR machine (Applied 
Biosystems) according to the manufacturer’s protocol. Ratio 
of input to the output signal was calculated.
Fluorescence microscopy. For binding with SK-BR-3 and 
MDA-MB-231 cells, 1 µM 3’-TAMRA-labeled aptamer was 
incubated with cells for 45 min at 4 oC. In the case of NIH- 
T6.7 cell line, cells were incubated with 500 nM aptamers for 
20 min at 37 oC. Following a series of two washing steps to 
remove unbound aptamers, fluorescence signal was detected 
using microscopy (Olympus) with 400 X magnification. 
Kd determination. Diluted S6 aptamer (10 nM to 1 µM) and 
pool in the binding buffer were incubated with 1 × 105 cells at 
4 oC for 45 min in 60 mm culture dish. After two-times washing, 
cells collected into eppendorf tube, then bound RNAs were 
eluted with same procedure as mentioned in the Cell-SELEX 
process. The amount of aptamers that were bound to the cells 
was quantified by qPCR. Saturation curves were plotted based 
on qPCR data and the dissociation constants of aptamer cal-
culated by non-linear regression analysis.
Western blot analysis. The expression of HER-2 protein in 
cultured cells was detected by Western blot analysis. Cells 
were washed twice in cold phosphate-buffered saline (PBS) 
and lysed in RIPA buffer (50 mM Tris-HCl pH 8.0, 150 mM 
NaCl, 1% NP-40, 0.5% sodium deoxycholate, and 0.1% SDS). 
After cell lysis at 4 oC for 30 min with vortexing, supernatant 
was collected after centrifugation of the samples at 12000 rpm 
for 10 min, and protein was quantified with Protein Assay 
Reagent (Pierce). 50 µg of protein was separated by SDS- 
PAGE and electrotransfered onto a polyninylidene difluoride 
(PVDF) membrane (Millipore). The blots were blocked with 
5% skim milk in Tris-buffered saline (TBS) at room tempera-
ture for 1 h and incubated with 1 : 500 diluted primary antibody 
overnight at 4 oC. The blots washed three times in TBS-Tween 
20 for 5 min and then incubated with 1 : 2000 diluted horse-
radish peroxidas-labeled goat anti-mouse IgG in TBS-Tween 
20 for 1 h at room temperature. After washing 5 times in TBS- 
Tween 20 for 6 min, the proteins were visualized with an en-
hanced chemiluminescence (ECL plus) reagent (Amersham 
Bioscience). Mouse monoclonal anti-c-ErbB2/c-Neu antibody 
and goat anti-mouse HRP conjugate were purchased from 
Calbiochem and BIO-RAD, respectively.
Results and Discussion
To isolate aptamers with high affinity and specificity to the 
native, membrane-presented form of HER-2, we performed 
Cell-SELEX using a well-known HER-2-overexpressing breast 
cancer cell line, SK-BR-3.16 We started the SELEX procedure 
by using a RNA library of 40 nt randomized region, with 3 × 
1013 complexity (Fig. 1). First, we performed positive selec-
tion by retrieving aptamers that bind to SK-BR-3 cells. After 
14 rounds of positive selection, the binding affinity of RNA 
library reached saturation (data not shown). For the next six 
rounds, we included negative selection using two separate 
methods in parallel (Fig. 1). For one selection, we used MDA- 
MB-231 cell line, another breast cancer cell line with little 
HER-2 expression, as a negative cell line, and removed any 
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Figure 1. Cell-SELEX Scheme. See the text for details. (+); positive 
selection, (-); negative selection.
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Figure 2. (A) (left panel) HER-2 expression level in SK-BR-3 and MDA-MB-231 cell lines was detected by western blot analysis. (Right panel) 
Affinity test using qPCR. Comparision of aptamer pool affinity before and after counter selection. si15R and m15R represent HER-2 siRNA 
treated SK-BR-3 and MDA-MB-231 counter SELEX product. (B) Sequence alignment of selected aptamers. (C) Affinity of 5’-TAMRA
labeled individual aptamer clones visualized by fluorescence microscopy.
aptamers that bind to this cell line. For the other selection, we 
adopted a novel negative selection strategy, by knocking-down 
HER-2 expression in SK-BR-3 using HER-2 specific siRNA. 
After siRNA treatment, we incubated aptamers with the cell 
line and removed any binders.
After negative selection, we performed affinity test using 
first counter SELEX product. As shown in Fig. 2a, both nega-
tive selection using negative cell line (MDA-MB-231), and 
siRNA-based negative selection resulted in good discrimi-
nation between two cell lines. This suggests that the negative 
selection using siRNA was successful.
After the successful enrichment of aptamers with high 
affinity to SK-BR-3 cells, individual aptamers were cloned and 
sequenced. Aptamers from two different counter-selection app-
roaches had similar sequences so that they were grouped 
together. We were able to group individual aptamer sequences 
into three groups, as shown in Fig 2b. Interestingly, Group II 
could be further divided into two subgroups, Group II-I and 
II-II (Fig. 2b). The two subgroups shared conserved 3’-half of 
the sequences, but there 5’-half sequences were divergent. In 
addition, we noticed that some aptamers had longer than 40 nt 
randomized region, suggesting that some sequences were 
inserted during the SELEX cycle. 
To visualize the binding of aptamer to breast cancer cell 
lines, we indirectly labeled individual aptamers by annealing 
with a tetramethylrhodamine (TAMRA)-labeled oligonucleo-
tide complementary to the 3’-constant region of aptamers. We 
then incubated the aptamers with breast cancer cell lines, and 
the bound aptamers were visualized by fluorescence micro-
scopy (Fig. 2c). Whereas pool RNA did not show strong 
affinity to both cell lines tested, selected aptamers showed 
preferential binding to SK-BR-3 cell line over MDA-MB-231 
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Figure 3. (A) secondary structure of S6 aptamer predicted by 
Mfold (B) Determination of the dissociation constant (Kd) for S6 
aptamer.
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Figure 4. Specificity of S6 aptamer against HER-2 overexpressing 
cells. (A) Affinity of 5’-TAMRA labeled S6 aptatmer to NIH3T6.7 
cells visualized by fluorescence microscopy. Aptamer was incubated
with cells for 20 min at 37 oC. (B) (left panel) HER-2 expression 
level in NIH3T6.7 cell line was detected by western blot analysis. 
(Right panel) Affinity test of S6 aptamer to NIH3T6.7 cells by qPCR 
at the same condition with (A).
cell line (Fig. 2c). Among these aptamers tested, the S6 aptamer 
showed strongest binding to the SK-BR-3 cell line but bound 
only weakly to the MDA-MB-231 cell line (Fig. 2c). Therefore, 
we further characterized S6 aptamer.
The secondary structure of S6 aptamer was predicted using 
Mfold program (Fig. 3a). We then measured the equilibrium 
dissociation constant (Kd) for the S6 aptamer by using a con-
stant number of cells incubated with varying concentrations 
of RNAs. Using a non-linear regression analysis, the Kd value 
of S6 aptamer was determined as 94.6 nM (Fig. 3b). 
While the S6 aptamer showed preferential binding to 
HER-2-overexpressing SK-BR-3 cells over HER-2-under-
expressing MDA-MB-231 cells, there is a possibility that the 
target of S6 aptamer may not be the HER-2 receptor, but 
another cell surface protein which is enriched more in SK- 
BR-3 cells than in MDA-MB-231 cells. To confirm that the S6 
aptamer targets the HER-2 receptor, we tested S6 aptamer’s 
affinity to NIH-3T3/HER2, a NIH-3T3 cell line overexpre-
ssing human HER-2. As shown in Fig. 4, both fluorescence 
microscopy analysis and RT-qPCR-based affinity test demon-
strated that S6 aptamer has higher affinity to the NIH-3T3/ 
HER2 cell line than to the original NIH-3T3 cell line. These 
data confirms that the target of S6 aptamer is the human 
HER-2 receptor, not other proteins expressed on the surface of 
SK-BR-3 cells.
In this study, using Cell-SELEX, we isolated RNA aptamers 
which can bind with high affinity and specificity to HER-2. 
We also developed a siRNA-based counter-selection approach, 
which could be broadly applied to future Cell-SELEX experi-
ments targeting specific cell surface receptors. The advantage 
of using siRNA-based counter-selection approach is that one 
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does not need to clone and express the receptor protein in 
unrelated cell lines to execute Cell-SELEX.
For in vivo diagnostic and therapeutic applications, the selected 
aptamers need to be optimized further. To confer resistance to 
serum nucleases, chemical modifications such as 2’-OMe or 
2’-F in the ribose sugar should be introduced.17 In addition, 
minimal domain required for HER-2 binding can be identified, 
and could be multimerized to maximize the avidity of aptamers 
against the target.18 Upon these modifications, the HER-2- 
targeting RNA aptamers could provide a starting point to 
develop novel strategies for in vivo diagnostics, targeted drug 
delivery, and therapeutic applications against breast cancer.
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